Media coverage about CareDx (NASDAQ:CDNA) has trended positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a news impact score of 0.29 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.4252116269409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Critical Comparison: CareDx (CDNA) versus Biocept (BIOC) (americanbankingnews.com)
- CareDx (CDNA) & Its Peers Head to Head Survey (americanbankingnews.com)
- CareDx (CDNA) Upgraded to Buy at ValuEngine (americanbankingnews.com)
- Head-To-Head Comparison: CareDx (CDNA) vs. Its Competitors (americanbankingnews.com)
- Financial Survey: CareDx (CDNA) versus Its Competitors (americanbankingnews.com)
Shares of CDNA opened at $8.47 on Friday. The company has a debt-to-equity ratio of -3.08, a quick ratio of 0.50 and a current ratio of 0.62. CareDx has a 12-month low of $0.76 and a 12-month high of $8.63.
A number of research firms have recently commented on CDNA. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of CareDx in a report on Wednesday, January 31st. Finally, ValuEngine downgraded CareDx from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. CareDx presently has an average rating of “Buy” and a consensus price target of $8.65.
In related news, insider Peter Maag sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 27th. The stock was sold at an average price of $7.87, for a total transaction of $118,050.00. Following the completion of the transaction, the insider now owns 272,037 shares in the company, valued at approximately $2,140,931.19. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.40% of the stock is currently owned by insiders.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.